Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023


Published Date : Jan 07, 2016

ALBANY, NY, Jan 7, 2016MarketResearchReports.biz has added a research report to its database on the pharmaceutical industry. The report, titled “Human Immunodeficiency Virus (HIV) - Global Drug Forecast And Market Analysis To 2023”, projects forecasts for the global market for therapeutic products for the Human Immunodeficiency Virus.

The report incorporates a regional reports of the global HIV therapeutics market, which covers the nine largest pharmaceutical markets in the world – China, Brazil, Japan, the U.K., Spain, Italy, Germany, France, and the U.S.

The report states that the global HIV therapeutics market, from the perspective of these major regional markets, is expected to witness a steady growth rate.

The primary driver for the growth of the global HIV therapeutics market is the highly anticipated launch of two novel drug categories, protease inhibitor-based STRs and novel integrase inhibitor-based STRs. These include darunavir/cobicistat/emtricitabine/TAF by Gilead and Janssen, Quad 2 (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]) by Gilead, and Triumeq (dolutegravir/abacavir/lamivudine) by ViiV Healthcare.

The report also marks the restraints acting on the global HIV therapeutics market, including the impending patent expirations of top-earning branded drugs in the U.S., Japan, the U.K., Spain, Italy, Germany, and France. The mandatory licensing of drugs and generic erosion in China and Brazil is expected to further impede the global HIV therapeutics market.

For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/487690

The key findings in the global HIV therapeutics market research report include the financial aspects of the market. The global HIV therapeutics market was valued at nearly US$14 bn in 2013. In terms of sales, the report expects this market to reach US$15 bn by the end of 2023, progressing at an estimated CAGR of 0.9% from 2014 to 2023.

The majority of these sales are expected to be derived from the U.S. market. One of the major hindrances affecting other regions is the set of financial austerity measures.

Another factor expected to drive the global HIV therapeutics market is an increase in the uptake of STRs. It is expected that the STRs based on INIs – predominantly launched by ViiV and Gilead as Triumeq and Quad 2, respectively – will lead the global HIV therapeutics market in the coming years.

The list of companies profiled in the global HIV therapeutics market research report includes ViiV Healthcare, Gilead Sciences, Janssen, Tobira Therapeutics, TaiMed Biologics, Avexa, Japan Tobacco, Bristol-Myers Squibb, Merck and Co., and AbbVie.

The scope of the report includes an overview of the global HIV therapeutics market through details on the symptoms, diagnosis, pathophysiology, etiology, and epidemiology strategies. The report also includes the current strategies employed in management aspects of the global HIV therapeutics market.

The report also includes the major pipeline products and sales along with the annual cost of therapy in the global HIV therapeutics market for the given forecast period. The report’s pipeline reports includes a descriptive data split that spans multiple phases. It also includes emerging novel trends, a descriptive reports of late-stage pipeline products, and synopses on all the early-stage projects and their innovative concepts.

To order report Call Toll Free: 866-997-4948 or send an email on sales@marketresearchreports.biz